AU2008216106C1 - Cancer treatment method - Google Patents

Cancer treatment method

Info

Publication number
AU2008216106C1
AU2008216106C1 AU2008216106A AU2008216106A AU2008216106C1 AU 2008216106 C1 AU2008216106 C1 AU 2008216106C1 AU 2008216106 A AU2008216106 A AU 2008216106A AU 2008216106 A AU2008216106 A AU 2008216106A AU 2008216106 C1 AU2008216106 C1 AU 2008216106C1
Authority
AU
Australia
Prior art keywords
human
cancer
carboxylic acid
syndrome
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008216106A
Other languages
English (en)
Other versions
AU2008216106B9 (en
AU2008216106B2 (en
AU2008216106A1 (en
Inventor
Connie Lynn Erickson-Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008216106(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2008216106A1 publication Critical patent/AU2008216106A1/en
Application granted granted Critical
Publication of AU2008216106B2 publication Critical patent/AU2008216106B2/en
Publication of AU2008216106B9 publication Critical patent/AU2008216106B9/en
Assigned to GLAXOSMITHKLINE LLC reassignment GLAXOSMITHKLINE LLC Request to Amend Deed and Register Assignors: SMITHKLINE BEECHAM CORPORATION
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: GLAXOSMITHKLINE LLC
Publication of AU2008216106C1 publication Critical patent/AU2008216106C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008216106A 2007-02-16 2008-02-15 Cancer treatment method Active AU2008216106C1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US60/890,236 2007-02-16
US89255207P 2007-03-02 2007-03-02
US60/892,552 2007-03-02
US90820507P 2007-03-27 2007-03-27
US60/908,205 2007-03-27
US94934707P 2007-07-12 2007-07-12
US60/949,347 2007-07-12
US95228907P 2007-07-27 2007-07-27
US60/952,289 2007-07-27
US96919207P 2007-08-31 2007-08-31
US60/969,192 2007-08-31
US97721607P 2007-10-03 2007-10-03
US60/977,216 2007-10-03
PCT/US2008/054046 WO2008101141A2 (en) 2007-02-16 2008-02-15 Cancer treatment method

Publications (4)

Publication Number Publication Date
AU2008216106A1 AU2008216106A1 (en) 2008-08-21
AU2008216106B2 AU2008216106B2 (en) 2013-07-11
AU2008216106B9 AU2008216106B9 (en) 2013-09-05
AU2008216106C1 true AU2008216106C1 (en) 2025-11-13

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008216106A Active AU2008216106C1 (en) 2007-02-16 2008-02-15 Cancer treatment method

Country Status (28)

Country Link
US (2) US20100075928A1 (OSRAM)
EP (1) EP2124547B3 (OSRAM)
JP (1) JP5511391B2 (OSRAM)
KR (1) KR101447763B1 (OSRAM)
CN (1) CN101662937B (OSRAM)
AR (1) AR065348A1 (OSRAM)
AU (1) AU2008216106C1 (OSRAM)
BR (1) BRPI0807940B8 (OSRAM)
CA (1) CA2678358C (OSRAM)
CR (1) CR10997A (OSRAM)
DK (1) DK2124547T6 (OSRAM)
EA (1) EA017715B1 (OSRAM)
ES (1) ES2675070T7 (OSRAM)
FI (1) FI2124547T4 (OSRAM)
HU (1) HUE038563T2 (OSRAM)
IL (2) IL200319A (OSRAM)
MA (1) MA31202B1 (OSRAM)
MX (1) MX2009008822A (OSRAM)
NZ (1) NZ579068A (OSRAM)
PE (1) PE20081784A1 (OSRAM)
PL (1) PL2124547T5 (OSRAM)
PT (1) PT2124547T (OSRAM)
SI (1) SI2124547T2 (OSRAM)
TR (1) TR201809010T4 (OSRAM)
TW (1) TW200906393A (OSRAM)
UY (1) UY30915A1 (OSRAM)
WO (1) WO2008101141A2 (OSRAM)
ZA (1) ZA200905532B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EA022915B1 (ru) * 2007-10-09 2016-03-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
JP2012528184A (ja) 2009-05-29 2012-11-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチンアゴニスト化合物の投与の方法
CN103079551A (zh) * 2010-09-01 2013-05-01 诺华有限公司 Hdac抑制剂与血小板减少症药物的组合
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
IL262746B (en) * 2016-05-06 2022-09-01 Taris Biomedical Llc A method for treating urothelial cancer in the lower system
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1207155A1 (en) * 1999-07-26 2002-05-22 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
US20040019190A1 (en) * 2000-05-25 2004-01-29 Erickson-Miller Connie J Thrombopoietin mimetics
WO2006047344A1 (en) * 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
CA2390095C (en) * 1999-11-10 2013-01-08 M. Rigdon Lentz Method and system to remove cytokine inhibitor in patients
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2001260661A1 (en) * 2000-05-30 2001-12-11 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
EP1284997B1 (en) * 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
JP4145655B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物
WO2002062775A1 (en) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
EA007481B1 (ru) * 2001-09-24 2006-10-27 Тоск, Инк. Цисплатиновые составы пониженной токсичности и способы их применения
EP2314586B1 (en) * 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
TWI280128B (en) * 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
WO2004096154A2 (en) 2003-04-29 2004-11-11 Smithkline Beecham Corporation Methods for treating degenerative diseases/injuries
WO2005118551A2 (en) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
AU2006318527A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods
BRPI0709286A2 (pt) 2006-03-15 2011-07-05 Ligand Pharm Inc processo de sìntese de compostos para modulção da atividade da trombopoietina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1207155A1 (en) * 1999-07-26 2002-05-22 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
US20040019190A1 (en) * 2000-05-25 2004-01-29 Erickson-Miller Connie J Thrombopoietin mimetics
WO2006047344A1 (en) * 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods

Also Published As

Publication number Publication date
EP2124547B3 (en) 2025-06-18
US20100075928A1 (en) 2010-03-25
AR065348A1 (es) 2009-06-03
SI2124547T1 (en) 2018-08-31
CN101662937A (zh) 2010-03-03
DK2124547T6 (da) 2025-09-01
IL200319A (en) 2015-05-31
SI2124547T2 (sl) 2025-07-31
IL238394B (en) 2018-05-31
DK2124547T3 (en) 2018-07-16
CA2678358A1 (en) 2008-08-21
BRPI0807940B1 (pt) 2020-10-27
WO2008101141A3 (en) 2008-10-16
HUE038563T2 (hu) 2018-10-29
AU2008216106B9 (en) 2013-09-05
PL2124547T3 (pl) 2018-08-31
PE20081784A1 (es) 2009-01-25
NZ579068A (en) 2012-05-25
EP2124547A4 (en) 2010-05-05
JP2010519221A (ja) 2010-06-03
EP2124547B2 (en) 2025-04-16
AU2008216106B2 (en) 2013-07-11
AU2008216106A1 (en) 2008-08-21
ES2675070T3 (es) 2018-07-06
TR201809010T4 (tr) 2018-07-23
CA2678358C (en) 2015-12-08
IL238394A0 (en) 2015-06-30
EP2124547A2 (en) 2009-12-02
BRPI0807940B8 (pt) 2021-05-25
BRPI0807940A2 (pt) 2013-07-30
MX2009008822A (es) 2009-08-28
JP5511391B2 (ja) 2014-06-04
WO2008101141A2 (en) 2008-08-21
CN101662937B (zh) 2014-03-12
PT2124547T (pt) 2018-07-04
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
EP2124547B1 (en) 2018-03-28
EA200970776A1 (ru) 2010-02-26
CR10997A (es) 2009-10-16
DK2124547T4 (da) 2025-08-04
KR101447763B1 (ko) 2014-10-07
UY30915A1 (es) 2008-09-02
FI2124547T4 (fi) 2025-07-29
ZA200905532B (en) 2010-04-28
TW200906393A (en) 2009-02-16
EA017715B1 (ru) 2013-02-28
IL200319A0 (en) 2010-04-29
ES2675070T7 (en) 2025-08-06
MA31202B1 (fr) 2010-02-01
PL2124547T5 (pl) 2025-08-04

Similar Documents

Publication Publication Date Title
AU2008216106C1 (en) Cancer treatment method
CN106170288B (zh) 药物化合物
CA2819410C (en) Substituted phthalazin-1(2h)-ones, preparation processes and medical uses thereof
DK2609091T3 (en) Pharmaceutically active compounds as AXL inhibitors
JP5261575B2 (ja) 化学化合物
US7951957B2 (en) Substituted benzimidazoles and their use for inducing apoptosis
ES2967119T3 (es) Compuestos inhibidores de metaloenzimas
PT1024138E (pt) Derivados de pirazole
SG173320A1 (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
JP2019519484A (ja) 芳香族スルホンアミド誘導体
CN103124730A (zh) 杂环炔苯类化合物及其药用组合物和应用
AU2005335298B2 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
HUE029370T2 (hu) Rákellenes aktivitású vegyületek
AU728360B2 (en) Thienylcyclohexanone derivatives as ligands of the gabaa alpha5 receptor subtype
AU2012204650A1 (en) Novel indole or indazole derivative or salt thereof
CN105980349A (zh) 苯甲酰胺和烟酰胺化合物及其使用方法
CN101747330A (zh) 吡啶基噻唑胺类化合物及其药用组合物和应用
EP1644338A1 (en) 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
JP2004504398A (ja) 抗腫瘍活性を有する２−（１ｈ−インドール−３−イル）−２−オキソ−酢酸アミド
CN103172577A (zh) 4-氨基喹唑啉及4-氨基喹啉类化合物及其用途
KR20210058277A (ko) 피롤로피리미딘, 피롤로피리딘, 인다졸 화합물 유도체 및 이를 포함하는 치료용 약학 조성물
KR20210132143A (ko) 신규한 pan-RAF 키나아제 저해제 및 이의 용도
HUT58330A (en) Process for producing diazine derivatives and pharmaceutical compositions containing them
WO2024029583A1 (ja) 新規ピラゾール誘導体及びその用途
WO2022188792A1 (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): GLAXOSMITHKLINE LLC

GD Licence registered

Name of requester: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 JUL 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 24 JUL 2025